Radiation Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain.
Radiation Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6.
The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required.
A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group.
A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring.
The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients.
去势抵抗性前列腺癌（CRPC）领域的知识发展迅速，新的治疗方法和影像学进展不断涌现。尽管如此，在多个领域仍然缺乏或非常有限的证据，临床医生需要针对最佳策略提供明确的指导。
URONCOR 小组采用改良 Delphi 法，将 116 个相关问题分为 7 个不同的 CRPC 管理主题，制定了一项共识声明。
对于提出的 93%的问题，达成了强烈的共识或一致意见。这七个主题分别是：CRPC 定义、有症状的患者、转移的诊断、CRPC 进展、M0 管理、M1 管理和序贯治疗以及治疗监测。
基于放射肿瘤学专家意见的建议旨在为癌症专家提供专家指导，并规范西班牙的 CRPC 患者管理，为不同的临床相关问题提供便利决策。
